Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications

by Veeraraghavan, Jamunarani, Ma, Jiacheng, Hu, Yiheng, Wang, Xiao-Song
Published in Breast Cancer Res Treat (2016)

Curcumin regulates low-LET γ-radiation induced NFκB dependent telomerase activity in human neuroblastoma cells

by Aravindan, Natarajan, Veeraraghavan, Jamunarani, Madhusoodhanan, Rakhesh, Herman, Terence S., Natarajan, Mohan
Published 2011

Radiation-triggered Tumor Necrosis Factor (TNF) α-NFκB Cross-signaling Favors Survival Advantage in Human Neuroblastoma Cells

by Veeraraghavan, Jamunarani, Natarajan, Mohan, Aravindan, Sheeja, Herman, Terence S., Aravindan, Natarajan
Published 2011

Irreversible EGFR Inhibitor EKB-569 Targets Low-LET γ-Radiation-Triggered Rel Orchestration and Potentiates Cell Death in Squamous Cell Carcinoma

by Aravindan, Natarajan, Thomas, Charles R., Aravindan, Sheeja, Mohan, Aswathi S., Veeraraghavan, Jamunarani, Natarajan, Mohan
Published 2011

Amplification of TLK2 Induces Genomic Instability via Impairing the G2/M Checkpoint

by Kim, Jin-Ah, Anurag, Meenakshi, Veeraraghavan, Jamunarani, Schiff, Rachel, Li, Kaiyi, Wang, Xiaosong
Published in Mol Cancer Res (2016)

Towards personalized treatment for early stage HER2-positive breast cancer

by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Nat Rev Clin Oncol (2019)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

by Li, Li, Lin, Ling, Veeraraghavan, Jamunarani, Hu, Yiheng, Wang, Xian, Lee, Sanghoon, Tan, Ying, Schiff, Rachel, Wang, Xiao-Song
Published in Breast Cancer Res (2020)

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

by Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel
Published in Breast (2017)

A novel neoplastic fusion transcript, RAD51AP1-DYRK4, confers sensitivity to the MEK inhibitor trametinib in aggressive breast cancers

by Liu, Chia-Chia, Veeraraghavan, Jamunarani, Tan, Ying, Kim, Jin-Ah, Wang, Xian, Loo, Suet Kee, Lee, Sanghoon, Hu, Yiheng, Wang, Xiao-Song
Published in Clin Cancer Res (2020)

Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers

by Kim, Jin-Ah, Tan, Ying, Wang, Xian, Cao, Xixi, Veeraraghavan, Jamunarani, Liang, Yulong, Edwards, Dean P., Huang, Shixia, Pan, Xuewen, Li, Kaiyi, Schiff, Rachel, Wang, Xiao-Song
Published in Nat Commun (2016)

Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers

by Veeraraghavan, Jamunarani, Tan, Ying, Cao, Xi-Xi, Kim, Jin-Ah, Wang, Xian, Chamness, Gary C., Maiti, Sourindra N., Cooper, Laurence J. N., Edwards, Dean P., Contreras, Alejandro, Hilsenbeck, Susan G., Chang, Eric C., Schiff, Rachel, Wang, Xiao-Song
Published 2014

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

by Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Published in Br J Cancer (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

by Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Published in NPJ Breast Cancer (2021)

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

by Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel
Published in Proc Natl Acad Sci U S A (2019)

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

by Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
Published in Mol Cancer Res (2019)

Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

by De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Clin Cancer Res (2019)

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis

by Schettini, Francesco, Pascual, Tomas, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix
Published in Cancer Treat Rev (2020)

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

by Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F
Published in J Natl Cancer Inst (2019)

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

by Xu, Xiaowei, De Angelis, Carmine, Burke, Kathleen A., Nardone, Agostina, Hu, Huizhong, Qin, Lanfang, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Heiser, Laura M., Wang, Nicholas, Ng, Charlotte K.Y., Chen, Edward S., Renwick, Alexander, Wang, Tao, Nanda, Sarmistha, Shea, Martin, Mitchell, Tamika, Rajendran, Mahitha, Waters, Ian, Zabransky, Daniel J., Scott, Kenneth L., Gutierrez, Carolina, Nagi, Chandandeep, Geyer, Felipe C., Chamness, Gary C., Park, Ben H., Shaw, Chad A., Hilsenbeck, Susan G., Rimawi, Mothaffar F., Gray, Joe W., Weigelt, Britta, Reis-Filho, Jorge S., Osborne, C. Kent, Schiff, Rachel
Published in Clin Cancer Res (2017)